Aegerion Pharmaceuticals, Inc. AEGR announced its plans to reduce its global workforce ... Aegerion is a Zacks Rank #2 (Buy) stock. Some better-ranked stocks in the health care sector include Actelion Ltd. ALIOF, Anika Therapeutics Inc. …
Aegerion Pharmaceuticals, Inc. AEGR announced that it has entered into a definitive ... Post completion, each outstanding share of Aegerion’s common stock will be exchanged for 1.0256 shares of QLT’s common stock. QLT will change its …
Aegerion Pharmaceuticals Inc : Aegerion Pharmaceuticals and QLT Inc. agree to strategic merger . Each outstanding share of Aegerion common stock will be exchanged for 1.0256 shares of QLT common stock . Broad-based investor …
Aegerion Pharmaceuticals, Inc.’s (AEGR) Juxtapid was approved in Canada as an adjunct ... We expect investor focus to remain on the HoFH drug going forward. Aegerion, a biopharma stock, currently carries a Zacks Rank #4 (Sell). Some …
Aegerion Pharmaceuticals (NASDAQ: AEGR) Aegerion is a biopharmaceutical company involved ... increasing total institutional holding by approximately 10%. The stock is trading near its mean sell side target price of $40.2. The …
The shares of Aegerion Pharmaceuticals surged after Sarissa Capital Management disclosed its stake in the company. The stock was trading at $25.70 per share, up by more than 8% to $25.87 per share at the time of this writing around …
Over the previous three months, the stock has advanced 0.54%. The Company's shares are trading above their 50-day …
The most up-to-date publicly available information on hedge funds comes from 13D and 13G filings, which take place shortly after a fund or other institutional investor owns over 5% of a stock’s outstanding shares (or makes changes to …
In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year. It's the prize that every biotech hopes to win – and every biotech investor hopes to cash in on. So how do you spot one in the …